EN | UA
EN | UA

Help Support

Back

Fixed dose betamethasone dipropionate and calcipotriene cream is beneficial to treat psoriasis

Fixed dose betamethasone dipropionate and calcipotriene cream is beneficial to treat psoriasis Fixed dose betamethasone dipropionate and calcipotriene cream is beneficial to treat psoriasis
Fixed dose betamethasone dipropionate and calcipotriene cream is beneficial to treat psoriasis Fixed dose betamethasone dipropionate and calcipotriene cream is beneficial to treat psoriasis

What's new?

For psoriasis, a cream containing fixed dose combination of calcipotriol and betamethasone dipropionate is better than the currently available topical suspension/gel.

For the topical management of plaque psoriasis, the new fixed dose combination of betamethasone dipropionate (BDP) and calcipotriol (CAL) cream based on PAD Technology (CAL/BDP PAD-cream) provides superior efficacy, enhanced patient quality of life, and equivalent favorable safety when compared to the currently marketed CAL/BDP topical suspension/gel [CAL/BDP TS], says a study published in The Journal of the European Academy of Dermatology and Venereology.

In this study, the data from two phase III,  randomized, multicenter, investigator-blind, active, and vehicle-controlled trials that recruited psoriasis people were pooled and evaluated. Investigational products included CAL/BDP PAD-cream designed for higher skin penetration and better patient preference, an active control (CAL/BDP TS), and a cream vehicle, that were applied once daily for eight weeks.

Both CAL/BDP PAD-cream and CAL/BDP TS were compared in terms of quality of life, safety,  and efficacy. For mitigating psoriasis, the new CAL/BDP PAD-cream formulation showed superior efficacy and safety following eight weeks of therapy. Compared to the CAL/BDP TS group, the  CAL/BDP PAD-cream group exhibited higher values for physician global assessment (PGA) therapeutic success, mean percent decline in modified Psoriasis Area and Severity Index (mPASI), and Dermatology Life Quality Index (DLQI) 0/1, as shown in Table 1:


There were no CAL/BDP PAD-cream-elicited adverse drug reactions with a frequency of >1%. Thus, CAL/BDP PAD-cream is better than CAL/BDP TS for the management of plaque psoriasis.

Source:

The Journal of the European Academy of Dermatology and Venereology

Article:

A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis

Authors:

A Pinter et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: